Canada markets close in 2 hours 8 minutes

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.71+0.37 (+5.04%)
As of 1:47PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close7.34
Open7.11
Bid7.74 x 800
Ask7.77 x 3000
Day's Range6.86 - 8.15
52 Week Range1.47 - 38.75
Volume592,884
Avg. Volume3,718,668
Market Cap51.236M
Beta (5Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateOct. 21, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 28, 2007
1y Target EstN/A
  • GlobeNewswire

    NeuroMetrix Reports Q3 2021 Financial Results

    WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.1 million was up slightly from Q3 2020. Gross margin on revenue was $1.4 million, a 70.0% gross margin rate. This was a decrease of 3.6 percentage points from $1.5 m

  • GlobeNewswire

    NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care

    WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based Care. Ms. Bell will be responsible for growing the Company's DPNCheck® business with a primary focus on the Medicare Advantage population, and more broadly, expanding the Company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast

  • Simply Wall St.

    Those who invested in NeuroMetrix (NASDAQ:NURO) a year ago are up 453%

    Some NeuroMetrix, Inc. ( NASDAQ:NURO ) shareholders are probably rather concerned to see the share price fall 55% over...